-
1 Comment
XBiotech Inc is currently in a long term downtrend where the price is trading 2.8% below its 200 day moving average.
From a valuation standpoint, the stock is 99.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 12.2.
XBiotech Inc's total revenue rose by inf% to $5M since the same quarter in the previous year.
Its net income has dropped by 100.3% to $-2M since the same quarter in the previous year.
Finally, its free cash flow grew by 30.5% to $-3M since the same quarter in the previous year.
Based on the above factors, XBiotech Inc gets an overall score of 3/5.
| Exchange | NASDAQ |
|---|---|
| Sector | Healthcare |
| CurrencyCode | USD |
| ISIN | CA98400H1029 |
| Industry | Biotechnology |
| PE Ratio | None |
|---|---|
| Target Price | 18 |
| Beta | 1.28 |
| Market Cap | 96M |
| Dividend Yield | None |
XBiotech Inc., a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and general inflammation. The company was incorporated in 2005 and is headquartered in Austin, Texas.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for XBIT using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
